Cobroxin Now Available at Winn-Dixie Supermarkets

Cobroxin Now Available at Winn-Dixie SupermarketsThe Award Winning Over-The-Counter (OTC) Pain Reliever, Cobroxin, is Now Available at Winn-Dixie Supermarkets Located Throughout the Southeastern United States

Nutra Pharma Corporation: XenaCare Holdings, Inc. On Tuesday February 16, 2010, 9:03 am
DELRAY BEACH, Fla. -- Nutra Pharma's (OTCBB:NPHC) distributor, XenaCare Holdings, Inc., a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that its award winning over-the-counter (OTC) pain reliever, Cobroxin, is now available at Winn-Dixie supermarkets located throughout the Southeastern United States. Winn-Dixie currently operates 515 stores in Florida, Georgia, Alabama, Mississippi, and Louisiana under the Winn-Dixie, Winn-Dixie Marketplace and SaveRite banners.

“As one of the largest food retailers in the United States, Winn-Dixie provides Cobroxin with significant retail coverage throughout the Southeastern United States,” explained Frank Rizzo, CEO of XenaCare Holdings. “We are excited to be working closely with Winn-Dixie to continue to build consumer awareness about our Cobroxin branded pain relievers,” he added.

Cobroxin is the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Many other Stage 2 drugs require prescriptions, including Tylenol 3, Percocet, and Vicodin. Cobroxin is currently available as an oral spray for treating migraine headaches, neck aches, shoulder pain, cramps, lower back pain, and neuralgia and is also available as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.

Additional benefits to Cobroxin include:
•All Natural
•Non-Addictive
•Non-Narcotic
•Non-Opiate
•Long Lasting

XenaCare Holdings was granted a license by Nutra Pharma Corporation (OTCBB:NPHC), the biotechnology company that developed and currently manufactures Cobroxin, to market and distribute Cobroxin within the United States.

About Nutra Pharma Corp.
Nutra Pharma Corporation (the "Company") operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The Company, through its subsidiaries, carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm, is developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), and pain in humans. Additionally, ReceptoPharm provides contract research services through its ISO class 5 and GMP certified facilities. The Company's wholly-owned medical devices subsidiary, Designer Diagnostics, engages in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases, such as Nontuberculous Mycobacteria (NTM). Nutra Pharma continues to identify intellectual property and companies in the biotechnology arena that it investigates about possibly acquiring or establish strategic partnerships with.

http://www.nutrapharma.com

http://www.Cobroxin.com

Undiscovered Equities is currently offering a complimentary trial subscription.
To view our newsletter on a complimentary trial basis and take advantage of our other services go to www.undiscoveredequities.com and join our email list on our home page.

Sincerely,

Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
101 Plaza Real, Suite 212
Boca Raton, FL 33432
www.undiscoveredequities.com